TABLE 7

Predicted net DDI vs. observed and associated geometric fold error assuming total plasma concentrations and interaction in the liver only (eq. 9) Predictions were made assuming an exclusively competitive mechanism, a TDI mechanism and a mixed mechanism.


Precipitant

DDI (Observed)

DDI Predicted (Competitive Mechanism)

GFE

DDI Predicted (TDI Mechanism)

GFE

DDI Predicted (Mixed Mechanism)

GFE
Avasimibe 0.27 1.6 5.8 1.0 3.7 0.63 2.3
Avasimibe 0.06 2.5 42 1.0 17 0.60 10
Bosentan 0.7 1.2 1.9 1.0 1.5 0.09 7.4
Carbamazepine 0.26 1.0 4.0 1.0 3.8 0.09 2.8
Ethinyl estradiol 1.2 1.0 1.1 1.1 1.1 1.0 1.1
Fluoxetine 0.87 1.1 1.2 3.5 4.1 2.5 2.8
Fluoxetine 1.0 1.1 1.1 3.5 3.5 2.5 2.5
Mibefradil 8.9 1.5 6.0 14 1.6 14 1.5
Mibefradil 8.4 1.5 5.6 14 1.7 14 1.6
Modafinil 0.42 1.0 2.5 1.0 2.4 0.19 2.2
Nafcillin 0.4 1.0 2.8 1.0 2.7 0.24 1.5
Nelfinavir 6.1 2.5 2.5 14 2.3 12 2.0
Nifedipine 1.0 1.0 1.0 1.0 1.0 0.71 1.5
Phenobarbital 0.39 1.0 2.7 1.0 2.6 0.10 3.9
Phenytoin 0.06 1.1 18 1.0 17 0.11 1.8
Pioglitazone 0.98 1.2 1.3 5.5 5.6 2.2 2.2
Pleconaril 0.7 1.0 1.5 1.0 1.5 0.17 3.9
Rifampin 0.03 1.0 36 1.0 36 0.09 3.3
Rifampin 0.08 1.0 12 1.0 12 0.09 1.1
Rifampin 0.12 1.0 8.8 1.0 8.7 0.09 1.3
Rifampin 0.05 1.0 20 1.0 20 0.09 1.8
Ritonavir 27 13.7 2.0 14 1.9 14 1.9
Rosiglitazone 0.88 1.0 1.2 2.4 2.7 1.8 2.0
Saquinavir 5.2 2.1 2.5 14 2.6 12 2.3
Troglitazone 0.62 1.8 3.0 14 22 13 21
Troleandomycin 3.8 1.1 3.4 6.4 1.7 2.0 1.9
Verapamil 2.9 1.1 2.7 10 3.5 3.3 1.2
Verapamil 4.7 1.1 4.4 10 2.2 3.3 1.4
Geometric mean fold error


7.1

6.7

3.2
  • Values highlighted in bold are above 2-fold